Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Aldara (Imiquimod) in Actinic Keratosis
NCT00116649Phase 4Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Jun 2005
- Primary completion
- May 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of imiquimod in actinic keratosis (AK), sponsored by Graceway Pharmaceuticals. Started Jun 2005; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00116649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116649.